nodes	percent_of_prediction	percent_of_DWPC	metapath
Medroxyprogesterone Acetate—AKR1C3—Doxorubicin—testicular cancer	0.276	0.544	CbGbCtD
Medroxyprogesterone Acetate—CYP2C8—Ifosfamide—testicular cancer	0.0669	0.132	CbGbCtD
Medroxyprogesterone Acetate—CYP2C9—Ifosfamide—testicular cancer	0.0467	0.092	CbGbCtD
Medroxyprogesterone Acetate—CYP2C8—Etoposide—testicular cancer	0.032	0.063	CbGbCtD
Medroxyprogesterone Acetate—CYP3A4—Ifosfamide—testicular cancer	0.0271	0.0535	CbGbCtD
Medroxyprogesterone Acetate—PGR—corpus luteum—testicular cancer	0.0251	0.15	CbGeAlD
Medroxyprogesterone Acetate—SHBG—seminiferous tubule of testis—testicular cancer	0.0236	0.142	CbGeAlD
Medroxyprogesterone Acetate—CYP2C9—Cisplatin—testicular cancer	0.0227	0.0447	CbGbCtD
Medroxyprogesterone Acetate—AR—scrotum—testicular cancer	0.0217	0.131	CbGeAlD
Medroxyprogesterone Acetate—AR—seminiferous tubule of testis—testicular cancer	0.0169	0.102	CbGeAlD
Medroxyprogesterone Acetate—CYP3A4—Vinblastine—testicular cancer	0.0144	0.0284	CbGbCtD
Medroxyprogesterone Acetate—SHBG—semen—testicular cancer	0.013	0.0783	CbGeAlD
Medroxyprogesterone Acetate—CYP3A4—Etoposide—testicular cancer	0.013	0.0256	CbGbCtD
Medroxyprogesterone Acetate—AR—semen—testicular cancer	0.00935	0.0562	CbGeAlD
Medroxyprogesterone Acetate—CYP3A4—Doxorubicin—testicular cancer	0.00885	0.0174	CbGbCtD
Medroxyprogesterone Acetate—HSD3B2—gonad—testicular cancer	0.00629	0.0378	CbGeAlD
Medroxyprogesterone Acetate—HSD3B2—female gonad—testicular cancer	0.00511	0.0307	CbGeAlD
Medroxyprogesterone Acetate—HSD3B2—testis—testicular cancer	0.00454	0.0272	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—seminal vesicle—testicular cancer	0.00367	0.0221	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—Podofilox—Etoposide—testicular cancer	0.0035	0.539	CbGdCrCtD
Medroxyprogesterone Acetate—HSD3B2—lymph node—testicular cancer	0.00329	0.0197	CbGeAlD
Medroxyprogesterone Acetate—PGR—Ovarian Infertility Genes—DAZL—testicular cancer	0.00314	0.341	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Vincristine—Vinblastine—testicular cancer	0.003	0.461	CbGdCrCtD
Medroxyprogesterone Acetate—AKR1C3—female gonad—testicular cancer	0.00216	0.013	CbGeAlD
Medroxyprogesterone Acetate—ESR1—embryo—testicular cancer	0.00207	0.0124	CbGeAlD
Medroxyprogesterone Acetate—SHBG—gonad—testicular cancer	0.002	0.012	CbGeAlD
Medroxyprogesterone Acetate—AR—seminal vesicle—testicular cancer	0.00198	0.0119	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—testis—testicular cancer	0.00191	0.0115	CbGeAlD
Medroxyprogesterone Acetate—SHBG—female gonad—testicular cancer	0.00162	0.00974	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—embryo—testicular cancer	0.00153	0.00918	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—HPGDS—testicular cancer	0.00147	0.16	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—female gonad—testicular cancer	0.00146	0.00878	CbGeAlD
Medroxyprogesterone Acetate—SHBG—testis—testicular cancer	0.00144	0.00864	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—seminal vesicle—testicular cancer	0.00144	0.00862	CbGeAlD
Medroxyprogesterone Acetate—AR—gonad—testicular cancer	0.00143	0.00861	CbGeAlD
Medroxyprogesterone Acetate—ESR1—gonad—testicular cancer	0.00141	0.00845	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—lymph node—testicular cancer	0.00139	0.00833	CbGeAlD
Medroxyprogesterone Acetate—PGR—testis—testicular cancer	0.0013	0.00778	CbGeAlD
Medroxyprogesterone Acetate—AR—female gonad—testicular cancer	0.00116	0.00699	CbGeAlD
Medroxyprogesterone Acetate—ESR1—female gonad—testicular cancer	0.00114	0.00687	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—gonad—testicular cancer	0.00104	0.00623	CbGeAlD
Medroxyprogesterone Acetate—AR—testis—testicular cancer	0.00103	0.0062	CbGeAlD
Medroxyprogesterone Acetate—ESR1—testis—testicular cancer	0.00101	0.00609	CbGeAlD
Medroxyprogesterone Acetate—PGR—lymph node—testicular cancer	0.000939	0.00564	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—female gonad—testicular cancer	0.000843	0.00506	CbGeAlD
Medroxyprogesterone Acetate—CYP2C8—testis—testicular cancer	0.000835	0.00502	CbGeAlD
Medroxyprogesterone Acetate—AR—lymph node—testicular cancer	0.000748	0.0045	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—testis—testicular cancer	0.000748	0.00449	CbGeAlD
Medroxyprogesterone Acetate—ESR1—lymph node—testicular cancer	0.000735	0.00441	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—Endoderm Differentiation—PRDM14—testicular cancer	0.000639	0.0695	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—lymph node—testicular cancer	0.000542	0.00326	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—Arachidonic acid metabolism—HPGDS—testicular cancer	0.00053	0.0577	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Aryl Hydrocarbon Receptor—HPGDS—testicular cancer	0.000262	0.0285	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—LKB1 signaling events—STK11—testicular cancer	0.000201	0.0219	CbGpPWpGaD
Medroxyprogesterone Acetate—HSD3B2—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	0.000153	0.0167	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Arachidonic acid metabolism—HPGDS—testicular cancer	0.000149	0.0162	CbGpPWpGaD
Medroxyprogesterone Acetate—Hypersensitivity—Cisplatin—testicular cancer	0.000127	0.000411	CcSEcCtD
Medroxyprogesterone Acetate—Bradycardia—Epirubicin—testicular cancer	0.000127	0.00041	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Ifosfamide—testicular cancer	0.000126	0.000408	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Ifosfamide—testicular cancer	0.000126	0.000407	CcSEcCtD
Medroxyprogesterone Acetate—Erythema multiforme—Methotrexate—testicular cancer	0.000126	0.000407	CcSEcCtD
Medroxyprogesterone Acetate—Neuropathy peripheral—Doxorubicin—testicular cancer	0.000126	0.000407	CcSEcCtD
Medroxyprogesterone Acetate—Urticaria—Etoposide—testicular cancer	0.000126	0.000406	CcSEcCtD
Medroxyprogesterone Acetate—Haemoglobin—Epirubicin—testicular cancer	0.000126	0.000405	CcSEcCtD
Medroxyprogesterone Acetate—Stomatitis—Doxorubicin—testicular cancer	0.000126	0.000405	CcSEcCtD
Medroxyprogesterone Acetate—Jaundice—Doxorubicin—testicular cancer	0.000126	0.000405	CcSEcCtD
Medroxyprogesterone Acetate—Abdominal pain—Etoposide—testicular cancer	0.000125	0.000404	CcSEcCtD
Medroxyprogesterone Acetate—Body temperature increased—Etoposide—testicular cancer	0.000125	0.000404	CcSEcCtD
Medroxyprogesterone Acetate—Urinary tract infection—Doxorubicin—testicular cancer	0.000125	0.000404	CcSEcCtD
Medroxyprogesterone Acetate—Hepatitis—Epirubicin—testicular cancer	0.000125	0.000403	CcSEcCtD
Medroxyprogesterone Acetate—Haemorrhage—Epirubicin—testicular cancer	0.000125	0.000403	CcSEcCtD
Medroxyprogesterone Acetate—Eye disorder—Methotrexate—testicular cancer	0.000125	0.000402	CcSEcCtD
Medroxyprogesterone Acetate—Tinnitus—Methotrexate—testicular cancer	0.000124	0.000401	CcSEcCtD
Medroxyprogesterone Acetate—Asthenia—Cisplatin—testicular cancer	0.000124	0.0004	CcSEcCtD
Medroxyprogesterone Acetate—Pharyngitis—Epirubicin—testicular cancer	0.000124	0.0004	CcSEcCtD
Medroxyprogesterone Acetate—Cardiac disorder—Methotrexate—testicular cancer	0.000124	0.000399	CcSEcCtD
Medroxyprogesterone Acetate—Sweating—Doxorubicin—testicular cancer	0.000123	0.000398	CcSEcCtD
Medroxyprogesterone Acetate—Urinary tract disorder—Epirubicin—testicular cancer	0.000123	0.000398	CcSEcCtD
Medroxyprogesterone Acetate—Oedema peripheral—Epirubicin—testicular cancer	0.000123	0.000397	CcSEcCtD
Medroxyprogesterone Acetate—Connective tissue disorder—Epirubicin—testicular cancer	0.000123	0.000396	CcSEcCtD
Medroxyprogesterone Acetate—Urethral disorder—Epirubicin—testicular cancer	0.000122	0.000395	CcSEcCtD
Medroxyprogesterone Acetate—Hepatobiliary disease—Doxorubicin—testicular cancer	0.000122	0.000393	CcSEcCtD
Medroxyprogesterone Acetate—Epistaxis—Doxorubicin—testicular cancer	0.000121	0.000392	CcSEcCtD
Medroxyprogesterone Acetate—CYP2C9—Arachidonic acid metabolism—HPGDS—testicular cancer	0.000121	0.0132	CbGpPWpGaD
Medroxyprogesterone Acetate—Angiopathy—Methotrexate—testicular cancer	0.000121	0.000391	CcSEcCtD
Medroxyprogesterone Acetate—Sinusitis—Doxorubicin—testicular cancer	0.000121	0.000389	CcSEcCtD
Medroxyprogesterone Acetate—Immune system disorder—Methotrexate—testicular cancer	0.000121	0.000389	CcSEcCtD
Medroxyprogesterone Acetate—Visual impairment—Epirubicin—testicular cancer	0.00012	0.000388	CcSEcCtD
Medroxyprogesterone Acetate—Mediastinal disorder—Methotrexate—testicular cancer	0.00012	0.000388	CcSEcCtD
Medroxyprogesterone Acetate—Chills—Methotrexate—testicular cancer	0.00012	0.000386	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Ifosfamide—testicular cancer	0.000119	0.000384	CcSEcCtD
Medroxyprogesterone Acetate—Diarrhoea—Cisplatin—testicular cancer	0.000118	0.000381	CcSEcCtD
Medroxyprogesterone Acetate—Erythema multiforme—Epirubicin—testicular cancer	0.000118	0.000381	CcSEcCtD
Medroxyprogesterone Acetate—Alopecia—Methotrexate—testicular cancer	0.000118	0.00038	CcSEcCtD
Medroxyprogesterone Acetate—Bradycardia—Doxorubicin—testicular cancer	0.000118	0.000379	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Plasma membrane estrogen receptor signaling—MMP2—testicular cancer	0.000117	0.0127	CbGpPWpGaD
Medroxyprogesterone Acetate—Mental disorder—Methotrexate—testicular cancer	0.000117	0.000377	CcSEcCtD
Medroxyprogesterone Acetate—Eye disorder—Epirubicin—testicular cancer	0.000117	0.000376	CcSEcCtD
Medroxyprogesterone Acetate—Hypersensitivity—Etoposide—testicular cancer	0.000117	0.000376	CcSEcCtD
Medroxyprogesterone Acetate—Tinnitus—Epirubicin—testicular cancer	0.000116	0.000376	CcSEcCtD
Medroxyprogesterone Acetate—Erythema—Methotrexate—testicular cancer	0.000116	0.000375	CcSEcCtD
Medroxyprogesterone Acetate—Malnutrition—Methotrexate—testicular cancer	0.000116	0.000375	CcSEcCtD
Medroxyprogesterone Acetate—Haemoglobin—Doxorubicin—testicular cancer	0.000116	0.000375	CcSEcCtD
Medroxyprogesterone Acetate—Cardiac disorder—Epirubicin—testicular cancer	0.000116	0.000374	CcSEcCtD
Medroxyprogesterone Acetate—Haemorrhage—Doxorubicin—testicular cancer	0.000116	0.000373	CcSEcCtD
Medroxyprogesterone Acetate—Hepatitis—Doxorubicin—testicular cancer	0.000116	0.000373	CcSEcCtD
Medroxyprogesterone Acetate—PGR—Signaling by ERBB4—KITLG—testicular cancer	0.000116	0.0126	CbGpPWpGaD
Medroxyprogesterone Acetate—Pharyngitis—Doxorubicin—testicular cancer	0.000115	0.00037	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—FOXM1 transcription factor network—MMP2—testicular cancer	0.000115	0.0125	CbGpPWpGaD
Medroxyprogesterone Acetate—Urinary tract disorder—Doxorubicin—testicular cancer	0.000114	0.000368	CcSEcCtD
Medroxyprogesterone Acetate—Oedema peripheral—Doxorubicin—testicular cancer	0.000114	0.000367	CcSEcCtD
Medroxyprogesterone Acetate—Dysgeusia—Methotrexate—testicular cancer	0.000114	0.000367	CcSEcCtD
Medroxyprogesterone Acetate—Asthenia—Etoposide—testicular cancer	0.000114	0.000366	CcSEcCtD
Medroxyprogesterone Acetate—Connective tissue disorder—Doxorubicin—testicular cancer	0.000114	0.000366	CcSEcCtD
Medroxyprogesterone Acetate—Angiopathy—Epirubicin—testicular cancer	0.000113	0.000365	CcSEcCtD
Medroxyprogesterone Acetate—Urethral disorder—Doxorubicin—testicular cancer	0.000113	0.000365	CcSEcCtD
Medroxyprogesterone Acetate—Immune system disorder—Epirubicin—testicular cancer	0.000113	0.000364	CcSEcCtD
Medroxyprogesterone Acetate—Mediastinal disorder—Epirubicin—testicular cancer	0.000113	0.000363	CcSEcCtD
Medroxyprogesterone Acetate—Back pain—Methotrexate—testicular cancer	0.000112	0.000362	CcSEcCtD
Medroxyprogesterone Acetate—Chills—Epirubicin—testicular cancer	0.000112	0.000361	CcSEcCtD
Medroxyprogesterone Acetate—Pruritus—Etoposide—testicular cancer	0.000112	0.000361	CcSEcCtD
Medroxyprogesterone Acetate—Visual impairment—Doxorubicin—testicular cancer	0.000111	0.000359	CcSEcCtD
Medroxyprogesterone Acetate—Alopecia—Epirubicin—testicular cancer	0.00011	0.000356	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Cisplatin—testicular cancer	0.00011	0.000354	CcSEcCtD
Medroxyprogesterone Acetate—Mental disorder—Epirubicin—testicular cancer	0.000109	0.000353	CcSEcCtD
Medroxyprogesterone Acetate—Erythema multiforme—Doxorubicin—testicular cancer	0.000109	0.000352	CcSEcCtD
Medroxyprogesterone Acetate—AR—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	0.000109	0.0119	CbGpPWpGaD
Medroxyprogesterone Acetate—Rash—Cisplatin—testicular cancer	0.000109	0.000351	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Cisplatin—testicular cancer	0.000109	0.000351	CcSEcCtD
Medroxyprogesterone Acetate—Malnutrition—Epirubicin—testicular cancer	0.000109	0.000351	CcSEcCtD
Medroxyprogesterone Acetate—Erythema—Epirubicin—testicular cancer	0.000109	0.000351	CcSEcCtD
Medroxyprogesterone Acetate—Diarrhoea—Etoposide—testicular cancer	0.000108	0.000349	CcSEcCtD
Medroxyprogesterone Acetate—Eye disorder—Doxorubicin—testicular cancer	0.000108	0.000348	CcSEcCtD
Medroxyprogesterone Acetate—Ill-defined disorder—Methotrexate—testicular cancer	0.000108	0.000348	CcSEcCtD
Medroxyprogesterone Acetate—Tinnitus—Doxorubicin—testicular cancer	0.000108	0.000347	CcSEcCtD
Medroxyprogesterone Acetate—Anaemia—Methotrexate—testicular cancer	0.000107	0.000346	CcSEcCtD
Medroxyprogesterone Acetate—Cardiac disorder—Doxorubicin—testicular cancer	0.000107	0.000346	CcSEcCtD
Medroxyprogesterone Acetate—Flatulence—Epirubicin—testicular cancer	0.000107	0.000346	CcSEcCtD
Medroxyprogesterone Acetate—Tension—Epirubicin—testicular cancer	0.000107	0.000344	CcSEcCtD
Medroxyprogesterone Acetate—Dysgeusia—Epirubicin—testicular cancer	0.000107	0.000343	CcSEcCtD
Medroxyprogesterone Acetate—Nervousness—Epirubicin—testicular cancer	0.000106	0.000341	CcSEcCtD
Medroxyprogesterone Acetate—Back pain—Epirubicin—testicular cancer	0.000105	0.000339	CcSEcCtD
Medroxyprogesterone Acetate—Angiopathy—Doxorubicin—testicular cancer	0.000105	0.000338	CcSEcCtD
Medroxyprogesterone Acetate—Malaise—Methotrexate—testicular cancer	0.000105	0.000338	CcSEcCtD
Medroxyprogesterone Acetate—Dizziness—Etoposide—testicular cancer	0.000105	0.000338	CcSEcCtD
Medroxyprogesterone Acetate—Muscle spasms—Epirubicin—testicular cancer	0.000105	0.000337	CcSEcCtD
Medroxyprogesterone Acetate—Immune system disorder—Doxorubicin—testicular cancer	0.000104	0.000337	CcSEcCtD
Medroxyprogesterone Acetate—Vertigo—Methotrexate—testicular cancer	0.000104	0.000337	CcSEcCtD
Medroxyprogesterone Acetate—Mediastinal disorder—Doxorubicin—testicular cancer	0.000104	0.000336	CcSEcCtD
Medroxyprogesterone Acetate—Chills—Doxorubicin—testicular cancer	0.000104	0.000334	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Cisplatin—testicular cancer	0.000103	0.000331	CcSEcCtD
Medroxyprogesterone Acetate—Alopecia—Doxorubicin—testicular cancer	0.000102	0.000329	CcSEcCtD
Medroxyprogesterone Acetate—Mental disorder—Doxorubicin—testicular cancer	0.000101	0.000327	CcSEcCtD
Medroxyprogesterone Acetate—Ill-defined disorder—Epirubicin—testicular cancer	0.000101	0.000325	CcSEcCtD
Medroxyprogesterone Acetate—Convulsion—Methotrexate—testicular cancer	0.000101	0.000325	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Etoposide—testicular cancer	0.000101	0.000325	CcSEcCtD
Medroxyprogesterone Acetate—Malnutrition—Doxorubicin—testicular cancer	0.000101	0.000324	CcSEcCtD
Medroxyprogesterone Acetate—Erythema—Doxorubicin—testicular cancer	0.000101	0.000324	CcSEcCtD
Medroxyprogesterone Acetate—Anaemia—Epirubicin—testicular cancer	0.000101	0.000324	CcSEcCtD
Medroxyprogesterone Acetate—Agitation—Epirubicin—testicular cancer	0.0001	0.000322	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Etoposide—testicular cancer	9.99e-05	0.000322	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Etoposide—testicular cancer	9.98e-05	0.000322	CcSEcCtD
Medroxyprogesterone Acetate—Headache—Etoposide—testicular cancer	9.92e-05	0.00032	CcSEcCtD
Medroxyprogesterone Acetate—Flatulence—Doxorubicin—testicular cancer	9.92e-05	0.00032	CcSEcCtD
Medroxyprogesterone Acetate—Chest pain—Methotrexate—testicular cancer	9.9e-05	0.000319	CcSEcCtD
Medroxyprogesterone Acetate—Myalgia—Methotrexate—testicular cancer	9.9e-05	0.000319	CcSEcCtD
Medroxyprogesterone Acetate—Arthralgia—Methotrexate—testicular cancer	9.9e-05	0.000319	CcSEcCtD
Medroxyprogesterone Acetate—Tension—Doxorubicin—testicular cancer	9.88e-05	0.000318	CcSEcCtD
Medroxyprogesterone Acetate—Dysgeusia—Doxorubicin—testicular cancer	9.86e-05	0.000318	CcSEcCtD
Medroxyprogesterone Acetate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	9.83e-05	0.000317	CcSEcCtD
Medroxyprogesterone Acetate—Malaise—Epirubicin—testicular cancer	9.81e-05	0.000316	CcSEcCtD
Medroxyprogesterone Acetate—Discomfort—Methotrexate—testicular cancer	9.78e-05	0.000315	CcSEcCtD
Medroxyprogesterone Acetate—Nervousness—Doxorubicin—testicular cancer	9.77e-05	0.000315	CcSEcCtD
Medroxyprogesterone Acetate—Vertigo—Epirubicin—testicular cancer	9.77e-05	0.000315	CcSEcCtD
Medroxyprogesterone Acetate—Syncope—Epirubicin—testicular cancer	9.75e-05	0.000314	CcSEcCtD
Medroxyprogesterone Acetate—Back pain—Doxorubicin—testicular cancer	9.73e-05	0.000314	CcSEcCtD
Medroxyprogesterone Acetate—Muscle spasms—Doxorubicin—testicular cancer	9.68e-05	0.000312	CcSEcCtD
Medroxyprogesterone Acetate—Palpitations—Epirubicin—testicular cancer	9.61e-05	0.00031	CcSEcCtD
Medroxyprogesterone Acetate—AR—Integrated Breast Cancer Pathway—STK11—testicular cancer	9.57e-05	0.0104	CbGpPWpGaD
Medroxyprogesterone Acetate—Confusional state—Methotrexate—testicular cancer	9.56e-05	0.000308	CcSEcCtD
Medroxyprogesterone Acetate—Loss of consciousness—Epirubicin—testicular cancer	9.56e-05	0.000308	CcSEcCtD
Medroxyprogesterone Acetate—Anaphylactic shock—Methotrexate—testicular cancer	9.49e-05	0.000306	CcSEcCtD
Medroxyprogesterone Acetate—Convulsion—Epirubicin—testicular cancer	9.42e-05	0.000304	CcSEcCtD
Medroxyprogesterone Acetate—Infection—Methotrexate—testicular cancer	9.42e-05	0.000304	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Etoposide—testicular cancer	9.41e-05	0.000303	CcSEcCtD
Medroxyprogesterone Acetate—Ill-defined disorder—Doxorubicin—testicular cancer	9.34e-05	0.000301	CcSEcCtD
Medroxyprogesterone Acetate—Nervous system disorder—Methotrexate—testicular cancer	9.3e-05	0.0003	CcSEcCtD
Medroxyprogesterone Acetate—Anaemia—Doxorubicin—testicular cancer	9.3e-05	0.0003	CcSEcCtD
Medroxyprogesterone Acetate—Thrombocytopenia—Methotrexate—testicular cancer	9.29e-05	0.000299	CcSEcCtD
Medroxyprogesterone Acetate—Chest pain—Epirubicin—testicular cancer	9.26e-05	0.000299	CcSEcCtD
Medroxyprogesterone Acetate—Arthralgia—Epirubicin—testicular cancer	9.26e-05	0.000299	CcSEcCtD
Medroxyprogesterone Acetate—Myalgia—Epirubicin—testicular cancer	9.26e-05	0.000299	CcSEcCtD
Medroxyprogesterone Acetate—Agitation—Doxorubicin—testicular cancer	9.25e-05	0.000298	CcSEcCtD
Medroxyprogesterone Acetate—Anxiety—Epirubicin—testicular cancer	9.23e-05	0.000297	CcSEcCtD
Medroxyprogesterone Acetate—Skin disorder—Methotrexate—testicular cancer	9.21e-05	0.000297	CcSEcCtD
Medroxyprogesterone Acetate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	9.2e-05	0.000296	CcSEcCtD
Medroxyprogesterone Acetate—Hyperhidrosis—Methotrexate—testicular cancer	9.17e-05	0.000296	CcSEcCtD
Medroxyprogesterone Acetate—Discomfort—Epirubicin—testicular cancer	9.15e-05	0.000295	CcSEcCtD
Medroxyprogesterone Acetate—Malaise—Doxorubicin—testicular cancer	9.08e-05	0.000293	CcSEcCtD
Medroxyprogesterone Acetate—Dry mouth—Epirubicin—testicular cancer	9.06e-05	0.000292	CcSEcCtD
Medroxyprogesterone Acetate—Vertigo—Doxorubicin—testicular cancer	9.04e-05	0.000291	CcSEcCtD
Medroxyprogesterone Acetate—Anorexia—Methotrexate—testicular cancer	9.04e-05	0.000291	CcSEcCtD
Medroxyprogesterone Acetate—Syncope—Doxorubicin—testicular cancer	9.03e-05	0.000291	CcSEcCtD
Medroxyprogesterone Acetate—Confusional state—Epirubicin—testicular cancer	8.95e-05	0.000289	CcSEcCtD
Medroxyprogesterone Acetate—AR—Regulation of nuclear beta catenin signaling and target gene transcription—MMP2—testicular cancer	8.9e-05	0.00968	CbGpPWpGaD
Medroxyprogesterone Acetate—Palpitations—Doxorubicin—testicular cancer	8.89e-05	0.000287	CcSEcCtD
Medroxyprogesterone Acetate—Anaphylactic shock—Epirubicin—testicular cancer	8.88e-05	0.000286	CcSEcCtD
Medroxyprogesterone Acetate—Oedema—Epirubicin—testicular cancer	8.88e-05	0.000286	CcSEcCtD
Medroxyprogesterone Acetate—Hypotension—Methotrexate—testicular cancer	8.86e-05	0.000286	CcSEcCtD
Medroxyprogesterone Acetate—Loss of consciousness—Doxorubicin—testicular cancer	8.85e-05	0.000285	CcSEcCtD
Medroxyprogesterone Acetate—Infection—Epirubicin—testicular cancer	8.82e-05	0.000284	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—ATF-2 transcription factor network—MMP2—testicular cancer	8.74e-05	0.00951	CbGpPWpGaD
Medroxyprogesterone Acetate—Shock—Epirubicin—testicular cancer	8.73e-05	0.000282	CcSEcCtD
Medroxyprogesterone Acetate—Convulsion—Doxorubicin—testicular cancer	8.72e-05	0.000281	CcSEcCtD
Medroxyprogesterone Acetate—Nervous system disorder—Epirubicin—testicular cancer	8.71e-05	0.000281	CcSEcCtD
Medroxyprogesterone Acetate—Thrombocytopenia—Epirubicin—testicular cancer	8.69e-05	0.00028	CcSEcCtD
Medroxyprogesterone Acetate—Tachycardia—Epirubicin—testicular cancer	8.66e-05	0.000279	CcSEcCtD
Medroxyprogesterone Acetate—Musculoskeletal discomfort—Methotrexate—testicular cancer	8.64e-05	0.000279	CcSEcCtD
Medroxyprogesterone Acetate—Skin disorder—Epirubicin—testicular cancer	8.62e-05	0.000278	CcSEcCtD
Medroxyprogesterone Acetate—PGR—Signaling by ERBB4—FGFR3—testicular cancer	8.59e-05	0.00934	CbGpPWpGaD
Medroxyprogesterone Acetate—Hyperhidrosis—Epirubicin—testicular cancer	8.58e-05	0.000277	CcSEcCtD
Medroxyprogesterone Acetate—Insomnia—Methotrexate—testicular cancer	8.58e-05	0.000277	CcSEcCtD
Medroxyprogesterone Acetate—Chest pain—Doxorubicin—testicular cancer	8.57e-05	0.000276	CcSEcCtD
Medroxyprogesterone Acetate—Arthralgia—Doxorubicin—testicular cancer	8.57e-05	0.000276	CcSEcCtD
Medroxyprogesterone Acetate—Myalgia—Doxorubicin—testicular cancer	8.57e-05	0.000276	CcSEcCtD
Medroxyprogesterone Acetate—Anxiety—Doxorubicin—testicular cancer	8.54e-05	0.000275	CcSEcCtD
Medroxyprogesterone Acetate—Paraesthesia—Methotrexate—testicular cancer	8.52e-05	0.000275	CcSEcCtD
Medroxyprogesterone Acetate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	8.51e-05	0.000274	CcSEcCtD
Medroxyprogesterone Acetate—Discomfort—Doxorubicin—testicular cancer	8.47e-05	0.000273	CcSEcCtD
Medroxyprogesterone Acetate—Anorexia—Epirubicin—testicular cancer	8.46e-05	0.000273	CcSEcCtD
Medroxyprogesterone Acetate—Dyspnoea—Methotrexate—testicular cancer	8.46e-05	0.000273	CcSEcCtD
Medroxyprogesterone Acetate—Somnolence—Methotrexate—testicular cancer	8.43e-05	0.000272	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	8.4e-05	0.00914	CbGpPWpGaD
Medroxyprogesterone Acetate—Dry mouth—Doxorubicin—testicular cancer	8.38e-05	0.00027	CcSEcCtD
Medroxyprogesterone Acetate—Dyspepsia—Methotrexate—testicular cancer	8.35e-05	0.000269	CcSEcCtD
Medroxyprogesterone Acetate—Hypotension—Epirubicin—testicular cancer	8.29e-05	0.000267	CcSEcCtD
Medroxyprogesterone Acetate—Confusional state—Doxorubicin—testicular cancer	8.28e-05	0.000267	CcSEcCtD
Medroxyprogesterone Acetate—Decreased appetite—Methotrexate—testicular cancer	8.25e-05	0.000266	CcSEcCtD
Medroxyprogesterone Acetate—Oedema—Doxorubicin—testicular cancer	8.21e-05	0.000265	CcSEcCtD
Medroxyprogesterone Acetate—Anaphylactic shock—Doxorubicin—testicular cancer	8.21e-05	0.000265	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal disorder—Methotrexate—testicular cancer	8.19e-05	0.000264	CcSEcCtD
Medroxyprogesterone Acetate—Fatigue—Methotrexate—testicular cancer	8.18e-05	0.000264	CcSEcCtD
Medroxyprogesterone Acetate—Infection—Doxorubicin—testicular cancer	8.16e-05	0.000263	CcSEcCtD
Medroxyprogesterone Acetate—Musculoskeletal discomfort—Epirubicin—testicular cancer	8.09e-05	0.000261	CcSEcCtD
Medroxyprogesterone Acetate—Shock—Doxorubicin—testicular cancer	8.08e-05	0.000261	CcSEcCtD
Medroxyprogesterone Acetate—Nervous system disorder—Doxorubicin—testicular cancer	8.05e-05	0.00026	CcSEcCtD
Medroxyprogesterone Acetate—Thrombocytopenia—Doxorubicin—testicular cancer	8.04e-05	0.000259	CcSEcCtD
Medroxyprogesterone Acetate—Insomnia—Epirubicin—testicular cancer	8.03e-05	0.000259	CcSEcCtD
Medroxyprogesterone Acetate—Tachycardia—Doxorubicin—testicular cancer	8.02e-05	0.000258	CcSEcCtD
Medroxyprogesterone Acetate—Skin disorder—Doxorubicin—testicular cancer	7.98e-05	0.000257	CcSEcCtD
Medroxyprogesterone Acetate—Paraesthesia—Epirubicin—testicular cancer	7.97e-05	0.000257	CcSEcCtD
Medroxyprogesterone Acetate—Hyperhidrosis—Doxorubicin—testicular cancer	7.94e-05	0.000256	CcSEcCtD
Medroxyprogesterone Acetate—AR—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	7.93e-05	0.00862	CbGpPWpGaD
Medroxyprogesterone Acetate—Dyspnoea—Epirubicin—testicular cancer	7.91e-05	0.000255	CcSEcCtD
Medroxyprogesterone Acetate—Somnolence—Epirubicin—testicular cancer	7.89e-05	0.000254	CcSEcCtD
Medroxyprogesterone Acetate—PGR—Signaling by ERBB4—KIT—testicular cancer	7.88e-05	0.00858	CbGpPWpGaD
Medroxyprogesterone Acetate—Anorexia—Doxorubicin—testicular cancer	7.83e-05	0.000252	CcSEcCtD
Medroxyprogesterone Acetate—Feeling abnormal—Methotrexate—testicular cancer	7.82e-05	0.000252	CcSEcCtD
Medroxyprogesterone Acetate—Dyspepsia—Epirubicin—testicular cancer	7.81e-05	0.000252	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal pain—Methotrexate—testicular cancer	7.76e-05	0.00025	CcSEcCtD
Medroxyprogesterone Acetate—Decreased appetite—Epirubicin—testicular cancer	7.72e-05	0.000249	CcSEcCtD
Medroxyprogesterone Acetate—Hypotension—Doxorubicin—testicular cancer	7.68e-05	0.000247	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal disorder—Epirubicin—testicular cancer	7.66e-05	0.000247	CcSEcCtD
Medroxyprogesterone Acetate—Fatigue—Epirubicin—testicular cancer	7.65e-05	0.000247	CcSEcCtD
Medroxyprogesterone Acetate—Constipation—Epirubicin—testicular cancer	7.59e-05	0.000245	CcSEcCtD
Medroxyprogesterone Acetate—AKR1C3—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	7.58e-05	0.00824	CbGpPWpGaD
Medroxyprogesterone Acetate—Urticaria—Methotrexate—testicular cancer	7.54e-05	0.000243	CcSEcCtD
Medroxyprogesterone Acetate—Abdominal pain—Methotrexate—testicular cancer	7.5e-05	0.000242	CcSEcCtD
Medroxyprogesterone Acetate—Body temperature increased—Methotrexate—testicular cancer	7.5e-05	0.000242	CcSEcCtD
Medroxyprogesterone Acetate—Musculoskeletal discomfort—Doxorubicin—testicular cancer	7.48e-05	0.000241	CcSEcCtD
Medroxyprogesterone Acetate—Insomnia—Doxorubicin—testicular cancer	7.43e-05	0.000239	CcSEcCtD
Medroxyprogesterone Acetate—Paraesthesia—Doxorubicin—testicular cancer	7.38e-05	0.000238	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Integrated Breast Cancer Pathway—STK11—testicular cancer	7.37e-05	0.00801	CbGpPWpGaD
Medroxyprogesterone Acetate—Dyspnoea—Doxorubicin—testicular cancer	7.32e-05	0.000236	CcSEcCtD
Medroxyprogesterone Acetate—Feeling abnormal—Epirubicin—testicular cancer	7.32e-05	0.000236	CcSEcCtD
Medroxyprogesterone Acetate—Somnolence—Doxorubicin—testicular cancer	7.3e-05	0.000235	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal pain—Epirubicin—testicular cancer	7.26e-05	0.000234	CcSEcCtD
Medroxyprogesterone Acetate—Dyspepsia—Doxorubicin—testicular cancer	7.23e-05	0.000233	CcSEcCtD
Medroxyprogesterone Acetate—PGR—Gene Expression—DNMT3L—testicular cancer	7.15e-05	0.00778	CbGpPWpGaD
Medroxyprogesterone Acetate—Decreased appetite—Doxorubicin—testicular cancer	7.14e-05	0.00023	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal disorder—Doxorubicin—testicular cancer	7.09e-05	0.000229	CcSEcCtD
Medroxyprogesterone Acetate—Fatigue—Doxorubicin—testicular cancer	7.08e-05	0.000228	CcSEcCtD
Medroxyprogesterone Acetate—Urticaria—Epirubicin—testicular cancer	7.05e-05	0.000227	CcSEcCtD
Medroxyprogesterone Acetate—Constipation—Doxorubicin—testicular cancer	7.02e-05	0.000226	CcSEcCtD
Medroxyprogesterone Acetate—Abdominal pain—Epirubicin—testicular cancer	7.02e-05	0.000226	CcSEcCtD
Medroxyprogesterone Acetate—Body temperature increased—Epirubicin—testicular cancer	7.02e-05	0.000226	CcSEcCtD
Medroxyprogesterone Acetate—Hypersensitivity—Methotrexate—testicular cancer	6.99e-05	0.000225	CcSEcCtD
Medroxyprogesterone Acetate—HSD3B2—Metabolism—HPGDS—testicular cancer	6.83e-05	0.00743	CbGpPWpGaD
Medroxyprogesterone Acetate—Asthenia—Methotrexate—testicular cancer	6.81e-05	0.000219	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Signaling by ERBB4—KITLG—testicular cancer	6.78e-05	0.00738	CbGpPWpGaD
Medroxyprogesterone Acetate—Feeling abnormal—Doxorubicin—testicular cancer	6.77e-05	0.000218	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal pain—Doxorubicin—testicular cancer	6.72e-05	0.000217	CcSEcCtD
Medroxyprogesterone Acetate—Pruritus—Methotrexate—testicular cancer	6.71e-05	0.000216	CcSEcCtD
Medroxyprogesterone Acetate—Hypersensitivity—Epirubicin—testicular cancer	6.54e-05	0.000211	CcSEcCtD
Medroxyprogesterone Acetate—Urticaria—Doxorubicin—testicular cancer	6.53e-05	0.00021	CcSEcCtD
Medroxyprogesterone Acetate—Body temperature increased—Doxorubicin—testicular cancer	6.49e-05	0.000209	CcSEcCtD
Medroxyprogesterone Acetate—Abdominal pain—Doxorubicin—testicular cancer	6.49e-05	0.000209	CcSEcCtD
Medroxyprogesterone Acetate—Diarrhoea—Methotrexate—testicular cancer	6.49e-05	0.000209	CcSEcCtD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—INSL3—testicular cancer	6.44e-05	0.00701	CbGpPWpGaD
Medroxyprogesterone Acetate—Asthenia—Epirubicin—testicular cancer	6.37e-05	0.000205	CcSEcCtD
Medroxyprogesterone Acetate—Pruritus—Epirubicin—testicular cancer	6.28e-05	0.000202	CcSEcCtD
Medroxyprogesterone Acetate—Dizziness—Methotrexate—testicular cancer	6.27e-05	0.000202	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	6.11e-05	0.00664	CbGpPWpGaD
Medroxyprogesterone Acetate—Diarrhoea—Epirubicin—testicular cancer	6.07e-05	0.000196	CcSEcCtD
Medroxyprogesterone Acetate—Hypersensitivity—Doxorubicin—testicular cancer	6.05e-05	0.000195	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Methotrexate—testicular cancer	6.03e-05	0.000194	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Methotrexate—testicular cancer	5.98e-05	0.000193	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Methotrexate—testicular cancer	5.98e-05	0.000193	CcSEcCtD
Medroxyprogesterone Acetate—Headache—Methotrexate—testicular cancer	5.94e-05	0.000192	CcSEcCtD
Medroxyprogesterone Acetate—Asthenia—Doxorubicin—testicular cancer	5.89e-05	0.00019	CcSEcCtD
Medroxyprogesterone Acetate—Dizziness—Epirubicin—testicular cancer	5.87e-05	0.000189	CcSEcCtD
Medroxyprogesterone Acetate—Pruritus—Doxorubicin—testicular cancer	5.81e-05	0.000187	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Epirubicin—testicular cancer	5.64e-05	0.000182	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Methotrexate—testicular cancer	5.63e-05	0.000182	CcSEcCtD
Medroxyprogesterone Acetate—Diarrhoea—Doxorubicin—testicular cancer	5.62e-05	0.000181	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Epirubicin—testicular cancer	5.6e-05	0.00018	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Epirubicin—testicular cancer	5.59e-05	0.00018	CcSEcCtD
Medroxyprogesterone Acetate—Headache—Epirubicin—testicular cancer	5.56e-05	0.000179	CcSEcCtD
Medroxyprogesterone Acetate—CYP2C8—Biological oxidations—HPGDS—testicular cancer	5.55e-05	0.00604	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Gene Expression—DNMT3L—testicular cancer	5.45e-05	0.00592	CbGpPWpGaD
Medroxyprogesterone Acetate—Dizziness—Doxorubicin—testicular cancer	5.43e-05	0.000175	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Epirubicin—testicular cancer	5.27e-05	0.00017	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Doxorubicin—testicular cancer	5.22e-05	0.000168	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Doxorubicin—testicular cancer	5.18e-05	0.000167	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Doxorubicin—testicular cancer	5.17e-05	0.000167	CcSEcCtD
Medroxyprogesterone Acetate—Headache—Doxorubicin—testicular cancer	5.15e-05	0.000166	CcSEcCtD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—INSL3—testicular cancer	5.08e-05	0.00553	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling by ERBB4—FGFR3—testicular cancer	5.04e-05	0.00548	CbGpPWpGaD
Medroxyprogesterone Acetate—HSD3B2—Metabolism—STK11—testicular cancer	4.97e-05	0.0054	CbGpPWpGaD
Medroxyprogesterone Acetate—Nausea—Doxorubicin—testicular cancer	4.88e-05	0.000157	CcSEcCtD
Medroxyprogesterone Acetate—ESR1—Signaling by ERBB4—KIT—testicular cancer	4.63e-05	0.00503	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Biological oxidations—HPGDS—testicular cancer	4.52e-05	0.00491	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Gene Expression—DNMT3L—testicular cancer	4.2e-05	0.00456	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—DNMT3L—testicular cancer	4.13e-05	0.0045	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—HPGDS—testicular cancer	3.38e-05	0.00367	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—INSL3—testicular cancer	2.98e-05	0.00324	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Biological oxidations—HPGDS—testicular cancer	2.98e-05	0.00324	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—H2AFZ—testicular cancer	2.95e-05	0.0032	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—KITLG—testicular cancer	2.71e-05	0.00295	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Gene Expression—H2AFZ—testicular cancer	2.5e-05	0.00272	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—STK11—testicular cancer	2.45e-05	0.00267	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	2.13e-05	0.00232	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—H2AFZ—testicular cancer	2.06e-05	0.00224	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—STK11—testicular cancer	2.05e-05	0.00223	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—FGFR3—testicular cancer	2.01e-05	0.00219	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Gene Expression—H2AFZ—testicular cancer	1.91e-05	0.00207	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—KITLG—testicular cancer	1.9e-05	0.00206	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—KIT—testicular cancer	1.85e-05	0.00201	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—testicular cancer	1.73e-05	0.00189	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—H2AFZ—testicular cancer	1.63e-05	0.00177	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—STK11—testicular cancer	1.62e-05	0.00176	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—KITLG—testicular cancer	1.5e-05	0.00163	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Gene Expression—H2AFZ—testicular cancer	1.47e-05	0.0016	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—H2AFZ—testicular cancer	1.45e-05	0.00157	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—FGFR3—testicular cancer	1.41e-05	0.00153	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—KIT—testicular cancer	1.29e-05	0.00141	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—FGFR3—testicular cancer	1.11e-05	0.00121	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—KIT—testicular cancer	1.02e-05	0.00111	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—H2AFZ—testicular cancer	9.55e-06	0.00104	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—STK11—testicular cancer	9.49e-06	0.00103	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—HPGDS—testicular cancer	9.49e-06	0.00103	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—KITLG—testicular cancer	8.78e-06	0.000955	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—HPGDS—testicular cancer	7.72e-06	0.00084	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—STK11—testicular cancer	6.9e-06	0.00075	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—FGFR3—testicular cancer	6.53e-06	0.00071	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—KIT—testicular cancer	5.99e-06	0.000652	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—STK11—testicular cancer	5.61e-06	0.00061	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—HPGDS—testicular cancer	5.09e-06	0.000554	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—STK11—testicular cancer	3.7e-06	0.000403	CbGpPWpGaD
